WELL Health Technologies Corp. (WELL) Earnings Call Transcript
May 7, 2026
Earnings Call Speaker Segments
Good afternoon, everyone, and thank you for joining the WELL Health Technologies Corp. First Quarter 2026 Conference Call. <<operator_script>> Today's call is being recorded on Thursday, May 7, 2026. At this point, I'll hand things over to Pardeep Sangha. Please go ahead.
Thanks, operator, and good morning, everyone — welcome to the conference call covering WELL Health's financial results for the first quarter of fiscal 2026, the period that closed on March 31, 2026. With me today are Hamed Shahbazi, our Chairman and CEO, and Eva Fong, the company's CFO. I believe everyone has seen the press release on our financial results that went out earlier today. Beyond historical performance, parts of today's call contain forward-looking information as defined under applicable securities laws, including future-oriented financial information and financial outlook information. Such forward-looking statements carry known and unknown risks, uncertainties, assumptions and other factors — many beyond WELL's control — that could cause actual results, performance or achievements of WELL to differ materially from the anticipated results, performance or achievements those forward-looking statements imply. Today's press release and our management discussion and analysis outline these factors further. Forward-looking statements are provided solely to give information about management's current expectations and plans relating to the future. Except as required by law, we do not undertake or accept any obligation or undertaking to publicly release updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions, assumptions or circumstances on which any such statement is based.
On this conference call, we might refer to several measures — adjusted gross profit, adjusted gross margin, adjusted EBITDA, adjusted EBITDA margin, shareholder EBITDA, adjusted net income, and adjusted free cash flow — and all of these are non-GAAP and non-IFRS figures. If you'd like more detail on the way we define these terms, please see the definitions provided in today's press release as well as in our management discussion and analysis. In the company's view, adjusted EBITDA represents a meaningful financial metric, since it captures cash produced by operations that the company can deploy toward funding working capital needs, servicing upcoming interest and principal debt repayments, and supporting future growth initiatives. Adjusted EBITDA should not be treated as a substitute for net income or loss as determined under IFRS. With that said, I'll now hand the call over to Mr. Hamed Shahbazi, Chairman and CEO of WELL Health Technologies.
Thanks, Pardeep, and hello everyone. We're grateful to all of you for being with us today. The first quarter got 2026 off to a strong start in nearly every area of our business. Revenue came in at $368.3 million, a rise of 25% compared with a year earlier. Adjusted EBITDA reached $43.1 million, up 56%. Adjusted net income was $15.5 million, double what it was last year. And Canadian clinics — the piece of WELL we've been highlighting to you most in recent weeks — posted 28% growth in adjusted EBITDA and is now positioned to comfortably surpass $0.5 billion in revenue this year. Beyond those headline figures, though, here's the message I hope you carry away from today's call. WELL is no longer merely Canada's biggest outpatient platform. We are turning into the operating system for modernizing the Canadian health care ecosystem. As we get started — as we'll discuss today, the policy landscape, the procurement landscape and the AI landscape are all coming together in our favor at once. Q1 marks the first quarter in which you can watch all 3 of these tailwinds start to appear in the financials at the same time, and we think the compounding effect is only getting underway. To give you a sense of the trajectory, our Q1 2025 revenue was $294 million, while Q1 2026 revenue was $368 million.
So that translates to $74 million in additional quarterly revenue over 12 months—more growth in one year than the whole company brought in during all of 2020, and that holds true even after stripping out every bit of deferred revenue recognized during the quarter. That kind of trajectory builds our confidence, not on account of what we happen to be at this moment, but because it shows the compounding character of our model remains intact. In our view, the conditions supporting that compounding are stronger now than they have ever been at any point in our history. Adjusted gross profit for the first quarter came in at $163.2 million, up 39% year-over-year versus Q1 2025. That gross profit gain stems mainly from a 440 basis point rise in our adjusted gross margin percentage, which reached 44.3%, and it was driven by higher-margin Healwell revenue being included along with growth in Wellstar revenue. In the quarter, we booked $12.8 million of previously deferred revenue tied to Circle Medical. -- we anticipate that Q2, the upcoming quarter, will be the last one affected by Circle Medical deferrals, which sets the business up for better comparability ahead. With those headline financials in mind, let me now move to the operational metrics underlying those results.
By the close of Q1 2026, WELL had more than 4,700 providers—both billable and nonbillable—delivering care through our network of physical and virtual clinics. Within that figure, we now collaborate with over 1,400 physicians in Canada, roughly 1.2% to 1.3% of every physician practicing in the country. Outside our own clinics, more than 44,000 health care providers throughout Canada—most of them physicians—benefit from Wellstar's SaaS and technology capabilities. We estimate that over 40% of all physicians in Canada engage with our Wellstar platform in some capacity. Patient visits were especially strong in Canada, hitting 1.3 million in Q1 2026, up more than 31% year-over-year, with organic growth of 13%, including both clinic absorptions and same clinic expansion. Across the whole system, including the U.S. and Canada, total patient visits rose 17% year-over-year to 1.9 million patient visits in the quarter. Organic growth system-wide came in at 6%. That slower organic growth rate was attributable to Circle Medical, where patient visits declined year-over-year because of the company's significant focus on compliance. We expect this headwind to improve later on this year. Strong financial operational results are the output of something more important than the real-world patient impact that our platform is delivering.
And now I want to walk through a handful of metrics that show what's behind these results — what's actually powering them. Every single day, WELL is creating tangible effects in health care, since our platform is generating value for providers as well as patients. Our tech stack, with the Wellstar platform at its head, concentrates on easing the administrative load that fuels burnout among physicians and admin staff. During Q1 2026, inside our WELL-owned clinic network, we used AI technology to automatically transcribe and mobilize data from 195,000 fax images, which cut errors considerably and freed up administrative time in the clinics. With our AI transcription tools, doctors throughout our network are reclaiming as much as 10 hours each week. That reclaimed time flows straight back into caring for patients. Here at HealWELL, we're improving patient outcomes by detecting disease earlier and optimizing care paths, and in Q1 2026 we have already screened more than 59,000 patient records for diseases. In Q1, our billing solutions group at Wellstar moved past $1 billion in annualized run rate when it comes to physician pay. Helping physicians with billing liberates them to concentrate on delivering more care. So this is important. Our patients are responding favorably — we reached an NPS, or Net Promoter Score, of roughly 80 in 2025, which sits well above the industry benchmark.
Regarding referrals, we're handling more than 160,000 e-referrals every month at present, which cuts down on paperwork and shortens waiting periods throughout the ecosystem. These aren't efficiencies that exist only in theory. They represent measured, repeatable gains achieved at scale right across our whole clinic network. That's the reason our providers are looking for additional patients. Our margins keep growing, and physicians increasingly prefer joining our network over running an independent practice. For listeners who are newer to the WELL story, I'd like to take a few minutes — or a few moments, I should say — to explain what underpins these results. WELL Health is Canada's largest outpatient health care platform, powered by software and AI. We have successfully built a comprehensive platform that integrates clinics delivering care, software that runs the platform, and AI that makes it smarter and faster. The WELL ecosystem consists of more than 250 clinics across the country, including primary care, diagnostics, specialty care and executive health clinics, which is home to over 4,700 practitioners, with tens of thousands of practitioners more who separately purchase and implement our digital products and services. Approximately 70% of the Canadian population now lives within 20 kilometers of the WELL location. Our clinics deliver the care, WellStar powers the digital workflows behind that care, and Healwell applies AI at enterprise scale while CyberWell protects the data.
No other Canadian business combines every one of these strengths. A smarter, better-connected, more prevention-focused health system requires a different sort of operating system. That is what we are constructing. In our view, the moment for such an operating system has never lined up better with the direction Canadian health care is taking—and that brings us to policy and regulation, which are generating substantial structural tailwinds for firms such as WELL. Federally, Bill S5, the Connected Care for Canadians Act, marks a significant change by requiring interoperability among health IT systems and by clearly limiting data blocking. Seen from an investor's angle, this essentially establishes a fresh benchmark for how health care technology has to work in Canada. The consequences matter. First, federal money and purchasing will probably cluster around platforms that meet these interoperability requirements. Second, scale grows more valuable, especially for platforms able to bring clinics, EMRs and AI together into one unified workflow. Third, it adds pressure on legacy vendors depending on closed ecosystems or point solutions, which may find adaptation difficult. And fourth—a point that is sometimes undervalued—compulsory data exchange substantially widens the cybersecurity exposure and the risk that comes with it.
Across the entire country, whenever information has to move between systems, each connection point turns into a possible weak spot for providers. We view that as a substantial chance for our CyberWell business to assist in safeguarding Canadian health care data, and that is precisely the reason we are moving CyberWell forward alongside third-party capital partners later this year. At the same time, on the provincial side, purchasing behavior is shifting, with an evident preference for sovereign platforms that are Canadian-owned. That matters especially in fields like clinical data infrastructure, AI and patient engagement layers. Three converging priorities are fueling this change: first, data sovereignty, making sure sensitive health data stays under Canadian control; second, regulatory alignment, making compliance simpler across jurisdictions; and third, economic policy, backing domestic innovation and infrastructure. Considered together, these federal and provincial forces are not separate. Their combined impact amounts to a strong tailwind toward a comprehensive Canadian-based health care technology company such as ours. WELL was purposely built and precisely built for this moment. WELL runs one of the largest outpatient clinic networks in the country, which anchors patient access and real-world data. Through Healwell, we possess robust data science and interoperability capabilities, and have added differentiated AI and clinical intelligence capabilities that sit on top of that data layer.
And with Wellstar, what we offer is a sovereign EMR platform that has substantial provider reach throughout Canada. Put together, that gives you a full end-to-end Canadian sovereign stack — covering care delivery along with data and intelligence — and it lines up directly with interoperability requirements as well as procurement driven by sovereignty. Our view is that no other health care company in Canada holds a comparable position. On March 19, 2026, the Health Minister of Ontario set out the province's plan for a province-wide primary care medical record initiative, aimed at advancing an integrated, interoperable electronic medical record system for primary care. That program sits within Ontario's primary care action plan, which carries backing of more than $3.4 billion in funding so that roughly 2 million additional residents get connected to primary care by 2029. The province has said it will run an open competitive procurement process, and it is looking into a multi-vendor approach to make sure the new system serves the varied needs of clinicians and patients throughout Ontario. WELL strongly backs this initiative for a new province-wide primary care medical record system, and we confirm our intention to take an active part in the upcoming procurement process that Supply Ontario will lead. Throughout the WELL family, we cover all three layers that the province of Ontario requires. First is WELL's clinic delivery network, made up of 120 WELL-owned and operated clinics in Ontario.
Next, there are WELL's EMR platforms, Nexus AI, and OceanMD. At present, WellStar supports and powers more than 8,100 physicians and 1,600 clinics throughout Ontario via its portfolio of provincially certified EMR platforms. As far as we know, Wellstar is the sole platform in Ontario today that brings together a provincially certified EMR, workflow automation that is fully integrated and AI-first, and complete interoperability with digital health network programs. Oscar Pro EMR from Wellstar is a platform certified by Ontario MD that already interoperates with Ontario's Health Report Manager and the Ontario Laboratories information system. And third, there is Healwell's interoperability plus AI layer. Through its Orion Health subsidiary, Healwell already supplies the province's 811 service, which offers advice to 15 million users, along with Healwell's Ontario Patient Viewer, a digital care record that consolidates patient data across care settings. Healwell's Darwin AI platform, which is award-winning and clinically validated, delivers ambient documentation, intelligent summary, and decision support solutions that directly address what Ontario needs. The announcement from the province of Ontario aligns directly with WELL's strengths and capabilities, among them interoperability across the broader health system, enhanced cybersecurity for patient data, reduced administrative burden for clinicians, and integration of modern tools such as electronic referrals and AI-enabled clinician automation. We believe WELL is uniquely positioned to serve as a primary partner to Ontario in delivering this vision.
Before I move on to the remainder of today's presentation, I'd like to lay out something fundamental about our thinking when it comes to WELL and the strategic choices you've watched us make. Every strategic step we're taking—from the strategic alternatives processes for our U.S. assets, to the Wellstar spinout, to bringing third-party capital partners into CyberWell—stems from one core belief: capital allocation discipline. As Canada's largest outpatient clinic operator, we can see a generational opportunity ahead. Right now we're at just under 1.5% of outpatient primary care. Our long-term goal is 10%, which works out to roughly a sevenfold rise in the share of Canadian care delivered through our network. That's the biggest opportunity in front of us and the one we hold the highest conviction in, and we believe it demands focus. If WELL's parent company capital were spread across multiple businesses, we'd risk both underinvesting in this generational Canadian opportunity and undercapitalizing the other businesses we own. So we've made a deliberate choice. WELL's parent capital is concentrated on Canadian clinics, including WELL Research—which you'll hear about later on this call—and which we believe represents the pharma activation of our clinic network, as well as one of the most promising byproducts of that network over time. Our other technology and adjacent businesses—Wellstar, Healwell and CyberWell—run as what we call strategically controlled platforms.
We keep strategic control. Minority financial partners supply growth capital and access to liquidity. Every platform finances its own expansion based on its own merits. What you're seeing is our planned activities — the U.S. strategic alternatives, the Wellstar spinout, and CyberWell's third-party capital partner process aren't separate decisions. They're a single strategy expressed in several ways. Now I'd like to turn to the additional topics we want to cover over the rest of today's presentation. First, a deep dive into our Canadian clinics business, including our M&A track record and pipeline. Second, I'll talk about some of the new growth-related initiatives we're undertaking as we scale our business for the future, including our WELL Health Intelligence platform, our new WELL research initiative, and the evolution of our CyberWell business into a new AI-focused platform. Third, I'll give an update on our strategically controlled technology businesses, Wellstar and Healwell AI. And lastly, an update on the strategic review processes for our U.S. assets. Let's now look at our WELL Canada business, which includes Canadian clinics, WellStar, and CyberWell, but excludes Healwell. WELL Canada generated revenue of $151.7 million in Q1 2026, an increase of 26% compared to the same period last year.
Canada is showing steady expansion, with adjusted EBITDA up 15% from Q1 '25 to Q1 '26, which matches the 15% increase seen a year earlier from Q1 '24 to Q1 '25. Over the last 2 years, adjusted EBITDA growth has landed at the top of our long-term goal of 10% to 15% adjusted EBITDA growth annually. Turning to our Canadian clinics business, performance there has been extremely robust. Revenue for our clinics business — spanning primary care, diagnostics, specialty care and longevity Health — has surpassed a 47% compound annual growth rate, or CAGR, across the past 4 years, and adjusted EBITDA for our Canadian clinic business rose at a CAGR of more than 44% during that same 4-year stretch. In Q1 '26, Canadian clinics brought in revenue of $130.3 million and remain on track to comfortably surpass $0.5 billion in Canadian clinics revenue in 2026. During Q1 2026, Canadian clinics posted adjusted EBITDA of $17 million, 28% higher than Q1 a year prior. Notably, WELL's Primary Care segment produced adjusted EBITDA margins of 8% in Q1 2026, roughly 200 basis points above the 6.2% recorded in Q1 2025. That gain stems from the combined effect of accretive acquisitions along with continued execution of WELL's clinic transformation program.
At the close of Q1 2026, our network of Canadian clinics stood at 253, versus 128 when Q1 2022 began. Let me frame our Canadian footprint in a longer-term perspective. Today we account for a share just shy of 1.5% of the outpatient primary care provided across Canada. This market is still highly fragmented. Over 8 to 10 years, we aim to reach a 10% share, and our internal modeling indicates we can get there even as we slow our growth to about half of today's rate over time. The opportunity ahead is large, and these goals are within reach. Turning to patient visits, our Canadian network recorded 1.3 million in Q1 '26, a 33% increase over 1 million in Q1 2025. Billable providers, meanwhile, numbered 2,204, which is 17% higher than in Q1 of last year. We keep bringing on more physicians than at any point before. The WELL brand is increasingly recognized as somewhere doctors can concentrate on caring for patients instead of clinic administration and charting. That proposition is delivering results. Patient visits keep rising faster than provider headcount, showing that productivity is improving network-wide. As the third graph illustrates, visits per billable provider rose 14% in Q1 '26 versus the same period a year earlier.
Although numerous elements play a part, we think our technology tooling—encompassing AI transcription and digital workflows—serves as a major catalyst behind the productivity gain we've seen. In concrete figures, during Q1 '26 our Canadian providers averaged roughly 576 patient visits for each billable provider, versus about 510 during the same quarter a year earlier. That represents genuine, measurable productivity improvement, and it reflects, operationally, our clinic transformation program and our AI tooling functioning exactly as intended. Turning now to recent M&A activity in Canada: during Q1 '26 we bought 3 clinics through 3 transactions, which brought in $34 million of annual revenue along with 77 additional providers. Although Q1 saw fewer transactions than recent quarters did, the average dollar value for each transaction was considerably larger in Q1 versus earlier quarters, thanks to the sizable eConsult platform business that we acquired in Alberta. We're quite happy with how our eConsult acquisition is progressing. As a reminder, this platform lets primary care physicians connect digitally and securely with specialists, obtaining timely clinical guidance asynchronously, which shortens wait times and strengthens care coordination among providers. Physicians and licensed health providers stay fully in charge of all clinical decisions. Our pipeline keeps expanding.
Right now, we have roughly $260 million in clinic revenue that's either under LOI or at an advanced stage — that spans 4 signed LOIs and 81 potential clinic opportunities. On the WELL Canada side, WellStar included, we're at about $265 million in revenue under LOI or in advanced stage, with 7 signed LOIs. When you look at the entire WELL Canada pipeline — pre-LOI targets, deals under LOI, and advanced stage — it adds up to more than 50 targets engaged, over $440 million in annual revenue, and more than 125 clinics. That's the biggest M&A pipeline WELL has ever had, and paired with the expanded $400 million senior credit facility that Eva will walk through shortly, it gives us solid visibility into our Canadian growth trajectory through 2026 and beyond. Before we move on, I'd like to take a moment on something foundational we're building that I think will shape WELL's next chapter — the WELL Health Intelligence Platform, or WIP. WIP is a unified data and AI foundation that brings together operational and financial information from across our subsidiaries into one secure, governed platform built specifically for AI mobilization. In its first phase, WIP represents a step change in how we manage performance and keep rapidly deploying AI across the organization.
What this provides is one unified—genuinely one single—source of truth, with standardized KPIs spanning each clinic, service line, and segment, plus real-time visibility for leadership. Reporting cycles that previously consumed weeks are going to shift to days, and ultimately to real time. Yet the strategic importance extends far past reporting. Our footprint spanning over 250 clinics ranks among WELL's most vital strategic assets. And the WELL Health Intelligence platform is the thing that compounds that edge. It converts scale into quicker decisions, more precise capital allocation, and greater operating leverage, while enabling us to take on future acquisitions without adding cost proportionately. Just as important, the WELL Health Intelligence platform serves as the launchpad for speeding up AI deployment at WELL. A unified, governed data layer is the necessary foundation for all our AI ambitions throughout the enterprise: predictive analytics, automated workflows, AI-generated learnings, and the patient, provider, and clinical experiences we are building going forward. Crucially, we are embedding Agenta capabilities straight into the WELL Health Intelligence platform—the capacity to deploy AI agents across finance, HR, IT, and other G&A functions so routine back-office work gets handled. As time goes on, we anticipate this becoming a meaningful lever for managing G&A costs while the business keeps scaling.
Right now we're putting money into the people and the technology we need to build WIP the right way, and we anticipate those investments will compound as time goes on. The WELL Health Intelligence platform serves as the base that makes possible the cost optimization program we're kicking off in the back half of the year, and I'll get into that shortly. Put simply, WIP is the infrastructure that allows the next chapter of WELL to happen. Our focus is on applying advanced AI and integrated technology to boost operating leverage as we scale. Over the coming months and heading into the second half of the year, we intend to roll out a comprehensive cost optimization program built to streamline internal processes, sharpen resource allocation and cut structural costs. We anticipate this program, together with the operational benefits that WIP delivers, will drive margin expansion in the back half of 2026 and on into 2027. We'll provide a further update in Q2 covering both the WELL Health Intelligence platform and our cost optimization efforts. Turning to the next item, I'm happy to announce the launch of WELL Research, which is the strategic consolidation of WELL's existing clinical research assets into one unified operating segment and brand serving the life sciences industry. WELL Research combines 4 differentiated assets that we already own: our 250-plus Canadian clinic network, our 44,000-plus provider network through Wellstar our patient consent platform, WELL Trust, and our AI-powered real-world evidence engine via DARWEN AI, which, of course, is part of HEALWELL.
For WELL, this is a significant strategic milestone and a meaningful step forward in how we approach clinical research. As you may remember, back in November 2025, WELL established a clinical research joint venture with Healwell — this includes a Toronto-based contract research organization, or CRO, called Biopharma Services, or BPSI. There's also a clinical site management organization, or SMO, called Clinical Phase Onward, also known as CPO. Let me spend a minute on how an SMO differs from a CRO, since I think that distinction matters. An SMO — a site management organization — is a service provider embedded directly inside clinical trial sites, like a physician practice or an outpatient clinic, to handle day-to-day trial execution: patient recruitment, study coordination, and protocol compliance. A contract research organization, or CRO, by contrast, works at a higher level, running whole trials across multiple sites on behalf of sponsors. Combined, these capabilities cover the entire clinical trial value chain — from identifying and consenting patients, through recruitment and trial execution, to generating real-world evidence. Before I go through BPSI, I want to connect this directly to something we introduced on our Q4 call: Welltrust. As a reminder, Welltrust is the consent-first platform that lets us mobilize patient data across our clinical network — with explicit, revocable patient consent — to match patients with the right clinical research opportunities.
Since Welltrust was brought to market last year — during the prior quarter — uptake across our network has kept expanding. And we remain on schedule for the formal launch — the commercial launch — of Welltrust later this year. WELL Research represents the logical and essential following step. The consent and identification layer comes from Welltrust, while the operating capability to actually conduct the trials comes from WELL Research. Combined, they turn what used to be a static clinic asset into an active, commercially viable research platform, and the two are built to be rolled out as a single integrated offering across the life sciences industry. BPSI contributes 15-plus years of operating history, over 2,200 completed clinical trials, 35-plus successful regulatory inspections and more than 20 industry awards. In the past, BPSI concentrated on lower-margin bioequivalent studies serving the generics market — a segment under structural pressure from rising price competition and a shift toward lower-cost international markets. Consequently, we are carrying out a phased transition. First, we are pivoting away from bioequivalence and generics toward Phase I trials for innovator drugs, which deliver materially higher margins. Second, a pull-through effect arises from these early-stage trials, driving larger and more profitable later-stage trials. And third, it is in those later-stage trials that additional competitive advantage is created by WELL's SMO capabilities driven by CPO along with the overall scale of WELL's clinical network.
We anticipate this shift will take up the remainder of 2026, as we reposition BPSI and push WELL Research toward profitability under the new model before the year is out. Taken together, that makes WELL Research a higher-value partner for the life sciences sector, with stronger economics down the road — to the point where it could represent a substantial upgrade to profitability and a commercial re-rating of the WELL clinic network. We'll keep you updated as we move forward on this. Now I'd like to walk you through some progress at our CyberWell business. Last month we announced that Cycura, Sekinu and PROACT — WELL's prior cybersecurity assets — have been folded into one cybersecurity organization called CyberWell, with leadership, governance and service delivery all centralized. This consolidated operating model runs on a new unified platform named Score, Fusion. We've also added a new group of seasoned executives to head up the effort at CyberWell, led by Jeff Engel, along with a newly formed advisory board whose members bring years of cybersecurity experience across national security, public policy and regulated industries. The threat landscape we operate in is one of escalating cyber threats. CyberWell's answer is anchored by Score Fusion, our proprietary AI-enabled cybersecurity platform.
Score Fusion brings together data from security operations, monitoring, and governance activities into one context-enriched view, using AI-driven analytics to spot patterns, reveal emerging risks, and provide predictive insight. Instead of offering point-in-time solutions, the platform enables continuous cyber resilience via intelligent automation and clear accountability spanning security, technology, and risk functions. In line with the strategically controlled platform approach I described earlier, we anticipate starting a process later this year to find like-minded financial partners who can fund CyberWell's growth while we keep strategic control. Let me briefly ground Wellstar's performance in the regulatory and policy backdrop we discussed earlier. In contrast to many SaaS businesses that currently face valuation pressure, Wellstar occupies the operational core of the clinics it serves—mission-critical infrastructure in a nondiscretionary sector. The interoperability mandates and sovereign procurement priorities we covered in the Canadian health care update not only bolster Wellstar's competitive position but also accelerate its strategic value as a Canadian-owned, certified, and fully integrated platform. Now let's turn to Wellstar's financial performance for the quarter. We're pleased to report that Wellstar posted yet another strong quarter, with revenue of $21.8 million, up 27% year-over-year. Wellstar reached MRR, or monthly recurring revenue, of $6.4 million at the end of Q1 2026, a rise of 38% compared with Q1 2025.
Adjusted EBITDA came in at $4.9 million for Q1 2026, which is up 14% from $4.3 million in adjusted EBITDA during Q1 2025. For Wellstar, adjusted EBITDA margins stood at 23% in Q1 '26. I'd like to highlight that this quarter included roughly $259,000 of prepubic related company costs tied to getting ready for our spinout plans. If you back those costs out, adjusted EBITDA would have reached $5.2 million, a 20% increase. Next, Healwell published its Q1 2026 financials earlier this afternoon as well. We take enormous pride in how far Healwell has come — a company whose launch we helped support. Healwell operates as a global health care software business offering enterprise-grade data science and AI, and it serves 70 of the biggest health systems in Canada and around the world across 11 countries, with customers that include the NHS in the U.K., the governments of France, Spain, Saudi Arabia, Abu Dhabi, New Zealand, and Australia, plus Health Systems in the United States. Healwell brought in revenue of $33.2 million in Q1 '26, a 316% year-over-year rise. Healwell additionally posted positive adjusted EBITDA of $735,000 in Q1 '26, versus a loss of $2.3 million in Q1 2025. Healwell's webcast conference call takes place tomorrow morning before the market opens.
I'd encourage you to tune in and hear Healwell's leadership talk about the progress they've made, and in particular some of their recent wins in AI and with health systems, which show the market is reacting positively to what they're doing. The next thing I want to address is the strategic review we're currently running on our U.S. assets. Naturally, there's a limit to how much we can share about these strategic review processes, particularly because some of our work here is at an advanced stage and we're in the middle of negotiations. Even so, I'll do my best to offer some high-level color. First, we're still committed to our strategy of pursuing strategic alternatives for the company's U.S. care delivery assets, which include WIS, Circle Medical and CRH. As on our last call several weeks ago, I can confirm that we're in active discussions with potential buyers for all three of those assets. We're handling these discussions deliberately and with discipline, so that we maximize value for our shareholders and secure the right long-term partners for these high-quality businesses. These strategic alternatives reflect the capital allocation discipline I mentioned earlier. We continue to like all of these businesses, but discipline matters. And we're considering multiple alternatives, not just divestitures. Whichever path we take will not compromise our ability to concentrate our capital resources and grow our Canadian clinic business.
I'd like to express our gratitude to you, our shareholders, for bearing with us while we drive these processes toward the proper conclusion. Let me now offer comments on each of the U.S. businesses, beginning with Wisp. Wisp brought in $29.1 million of revenue in Q1, versus $29.5 million in Q1 a year earlier. Adjusted EBITDA came in at a loss of $0.9 million, compared with $0.5 million in Q1 2025. Although revenue held steady, adjusted EBITDA mirrors deliberate investments meant to bolster WI's position over the long term. Those investments encompass compliance and clinical excellence, product innovation through new launches, among them a new mobile app rolled out recently, with additional enhancements slated for later this year. Strategic diversification is another, via a new B2B vertical propelled by a small acquihire that we closed at the start of the year, which complements the direct-to-consumer model. Measurable operational improvement is already emerging from these investments, and we anticipate W returning to EBITDA profitability during the second half of the year. Turning next to Circle Medical. Circle Medical posted $36 million of revenue in Q1, up 21%. That revenue, however, included roughly $12.8 million of net deferred revenue. Normalized adjusted EBITDA at Circle Medical was $2.9 million in Q1, having risen sequentially from the prior quarter.
We anticipate only a small deferred revenue effect — roughly $4.8 million — which will be recognized in Q2 2026, and nothing beyond that. In addition, as we mentioned on our previous conference call, we have an agreement in principle with U.S. regulators concerning the billing matters we described last year during our Q4 2024 conference call. We're eager to wrap up these arrangements and report back to shareholders. Lastly, CRH and provider staffing. Our combined CRH anesthesia and staffing business brought in $111.3 million in Q1 2026, versus $114.3 million in Q1 2025. Although the CRH anesthesia business rose 7% year-over-year, overall revenue dipped slightly because of a decline in the staffing business, which can be somewhat lumpy. Adjusted EBITDA for the combined anesthesia services and staffing came to $17.9 million in Q1 2026, compared with $17.6 million in Q1 2025. Even though growth was challenging in Q1 2026, we actually saw EBITDA margins improve across the combined businesses. At this point I'd like to hand the call to Eva.
Thanks, Hamed. When it comes to our capex, the underlying idea is investing for what lies ahead. Capital expenditures during Q1 2026 rose 88% compared with Q1 2025. The main drivers are the acquisition of Healwell plus our stepped-up future-oriented investments. The capital expenditure increase stems from the following items: first, the Canada clinic transformation and new diagnostic equipment; second, the recently launched WELL Research program; third, growth in CyberWell's new AI-focused platform; and fourth, higher AI-related capital expenditure at WELL Corporate, including the WELL Health Intelligence platform that Hamed mentioned earlier. Revenue for Q1 2026 was up 25% year-over-year, reaching $368 million. Even after setting aside the Healwell addition and the net impact of Circle Medical deferrals, the underlying business delivered roughly $22 million in net growth. Adjusted EBITDA posted strong year-over-year growth even with meaningful investments in WELL Research, CyberWell and the World Intelligence platform. We anticipate that these investment pressures will ease over the coming quarters, and once that happens the platform's underlying margin expansion will become more visible. Now to adjusted net income. Adjusted net income doubled, reaching $15.5 million in Q1 2026 versus $7.5 million in Q1 2025. Adjusted net income took a negative hit from our new growth initiatives, including WELL Research, CyberWell and the AI and IT transformation initiatives.
Operating adjusted free cash flow that's attributable to shareholders came in at $1.6 million for Q1 2026, versus $11.8 million in Q1 2025. Several things weighed on adjusted free cash flow: higher spending on growth initiatives, including -- well, Research, CyberWell and the AI-related transformation; the investments I mentioned earlier in the call tied to WIS; elevated capital expenditures as we discussed; and greater cash taxes relative to Q1 2025, driven by the timing of cash payments and better profitability at certain subsidiaries. In our view, this hit to adjusted free cash flow is temporary. Once our investment phase for growth initiatives normalizes, we anticipate adjusted free cash flow conversion will improve meaningfully through the back half of 2026 and on into 2027. Now turning to our balance sheet as of March 31, 2026. WELL closed Q1 2026 with a solid balance sheet, holding $134 million in cash and cash equivalents. We continue to be in good standing and fully compliant with every covenant tied to our 2 credit lines, JPMorgan in the U.S. and Royal Bank in Canada. Outstanding debt under those credit lines stood at roughly CAD 444.8 million as of March 31, 2026. That figure excludes Hall's credit facility with the Bank of Nova Scotia, which is likewise in good standing, with outstanding debt of $48.5 million.
In Q1 2026, we grew and prolonged our senior secured credit facility to CAD 400 million, plus a $100 million uncommitted accordion, under a syndicate led by Royal Bank of Canada, JPMorgan and TD Bank. That essentially doubles the capacity we had before and pushes the maturity out to January 2030. With this stronger facility, we gain considerable financial flexibility to carry out our Canadian acquisition pipeline, which, as Hamed mentioned earlier, is the biggest one we have ever had. During Q1, we kept up our normal course issuer bid, or NCIB. In Q1 2026, the company repurchased 177,600 shares. We expect to keep going with our share buyback program through the remainder of 2026 as permitted. I'm also glad to say that we hold the cash and available resources needed to keep funding our organic and inorganic growth program, which is focused on Canadian clinics and North Star. That wraps up my financial update, and I'll now hand the call back to Hamed.
Thanks, Eva. We're glad to restate the outlook we've given for fiscal 2026. Annual revenue should land between $1.55 billion and $1.65 billion, which works out to reported growth of 11% to 18%, and normalized growth of 16% to 22% once you strip out any effect from Circle Medical deferrals. Adjusted EBITDA should come in between $175 million and $185 million. That outlook factors in roughly $17.6 million of Circle Medical deferred revenue that we anticipate recognizing in 2026, and that revenue brings an EBITDA contribution near 100%. It also reflects only the acquisitions we've announced so far. Once you set aside the Circle Medical deferral effects and look at earnings on a normalized basis, we expect the company to keep performing the way it has in prior years — delivering adjusted EBITDA growth above 10% annually along with free cash flow growth, acquisitions included. The timing of further M&A and divestitures can move this outlook, and we'll keep the market posted as needed. Turning to WELL Canada in particular, which takes in the Canadian clinics plus Wellstar, we posted adjusted EBITDA growth of more than 44% in 2025, and within the coming 12 months we're aiming for roughly $800 million of revenue and more than $100 million of adjusted EBITDA on a run rate basis.
Just to remind everyone, over the last few years we've built a substantial outpatient clinic platform, and it now gives us a solid base for scalable growth. By bringing AI and advanced technology into our operations, we're actively improving our operating leverage and generating greater efficiencies throughout the business. To reinforce our financial position further, we anticipate launching a targeted cost optimization program during the second half of the year, designed to lower structural costs and widen margins as we keep scaling. And as mentioned earlier, the company remains fully committed to disciplined capital allocation, with its Canadian clinic program as the main destination for incremental capital. That focus is the central rationale behind the company's intention to move ahead with the spinout of Wellstar and its continuing evaluation of strategic alternatives for its U.S. care delivery assets. To close, Q1 2026 showed that WELL's model compounds. We posted record first quarter results, sped up our Canadian growth engine, strengthened our balance sheet and advanced value unlocking initiatives across our network. The strategic clarity we have today, built around being the operating system for modernizing Canadian health care, puts us in a strong position for the years ahead.
I want to express appreciation to our Board of Directors, to our senior leadership group throughout each of the company's many operating subsidiaries, and to every one of our employees and contractors. Specifically, my thanks go out to our health care practitioners and frontline workers, who deliver highly skilled patient care daily and make a difference in patients' lives. Thank you all for being with us today, and thank you as well to our shareholders, investors and analysts for their ongoing support. We will now take questions. Operator?
<<operator_script>> Our initial question is from Gianluca Tucci at Haywood Securities.
And Emma, congratulations on the quarter. Hamed, the Canadian business looks quite strong. As you keep adding clinics to the network, where do you see margins scaling to in primary care as you reach that 10% market share goal?
Yes. Thank you, Gianluca. The margin expansion we're seeing is very much deliberate—it isn't accidental. And we want those margins to keep rising. Honestly, our aim is to reach well into the double digits eventually. So I'd say you should keep seeing—expect to keep seeing—gains there over the near term.
Alright. Now shifting focus to the Ontario EMR opportunity. If everything lined up ideally, how would you picture WELL Health, CyberWell, Healwell, and even Wellstar coming together to go after this RFP or RFQ? And has the timing around the Wellstar spinout shifted now that this opportunity is on the table?
Yes. And so we have been extremely active in coordinating across our various different units, and we're going to present a really compelling solution. As I said during my scripted remarks on the call, we do expect this to be a multi-vendor solution. We've now heard some indications to that effect. And that really makes a lot of sense when you consider that there are 3 substantial vendors of size in the Ontario marketplace there with ourselves and TELUS Health and Loblaws. And so I think there are going to be aspects of this RFP that are going to create new opportunities for new business. As I noted, the budget is fairly significant for what Ontario is trying to achieve, but it will likely involve the involvement of multiple vendors. So I think we're in a really good position here. And this is why we spent some valuable airtime talking about the combined benefits of our proposal that we're going to put forth.
Justin Keywood of Stifel has the next question.
Good to see these results. As for the goal of growing Canada to $800 million in sales, the timeline appears to have moved up by roughly 1 quarter versus what was said in the March update. Is that a sign of greater confidence in the organic growth outlook, or is it that some of these files are progressing a little faster than expected?
Thanks, Justin. I appreciate you picking up on that. Yes, you've got it right. Since our previous conference call, we've moved the timeline up somewhat, and we're genuinely happy that we can do so. And yes, without question, that does show a degree of confidence that a number of these files are progressing. As you're aware, freeing up some upside — unblocking part of the capital resource capabilities and having that upsized facility in place does give us the ability to be somewhat more ambitious. Naturally, as you know, we're highly disciplined about keeping leverage levels reasonable, and we'll keep doing so. But yes, we do have some confidence that we'll hopefully be able to push this along somewhat faster than we previously expected.
Our following question is from Douglas Miehm at RBC Capital Markets.
This may tie into what was just asked. Regarding the bottleneck for bringing on this additional revenue and how many clinics you'll need to absorb — have you worked that out? I realize previously this was among the factors that prevented you from proceeding with every acquisition available, which you likely could have completed then. And I'm curious whether that has gotten substantially better, or whether you anticipate improvement in the near term.
Yes. Excellent question. So, Doug, I believe we have been quite deliberate when it comes to strengthening the organization's capacity to handle acquisitions of this larger size. I would add as well that this shows up in the margins. We are also now going after assets that could be seen as being of higher quality, which carry a stronger margin impact and likely require somewhat less transformation. Naturally, we will still transform those assets. We will still deploy our software, but they arrive in the network with stronger structural margins and stronger operations. As you can see, we are not completing as many absorptions. We continue to do them, but they demand considerable time and effort from our team, and we truly want to direct our clinic transformation teams toward the highest-leverage opportunities we humbly can. So we are being highly deliberate about genuinely lifting the margins in this business as we reach that $800 million goal.
That's quite reasonable. So, just a brief follow-up on what you said. Considering improved margins and the apparently larger scale of these clinics, would you anticipate paying a higher price for them? And perhaps you could discuss the rise in EBITDA multiples that could come with that? I'll stop there.
Yes. In certain instances, we might pay a bit more, but from what we can observe, we're confident that the implied multiples will, over time, keep mirroring our historical experience — namely IRR rates above 20%. All our activities and all the opportunities on our radar do align with those kinds of IRRs, and we remain firmly dedicated to that. So, on balance, as time goes on, we think these will in fact trade at stronger implied multiples.
Our following question is from Michael Freeman at Raymond James.
Congrats on the quarter. It's good to see that figure for visits per billable provider climbing as time goes on. And I'm wondering: how much room do you think there is when it comes to provider utilization? Does a natural ceiling exist there? In other words, how do you expect that to grow down the road?
Yes. That's a very fair question, Michael. As you know, this is a statistic we began publicly tracking and reporting on a few quarters back, and the trends we're seeing remain quite strong. We feel a great deal of confidence in our ability to keep delivering the tools, and we genuinely believe that as Wellstar rolls out and further expands its Agentic AI platform, this number could climb yet again. Naturally, that takes time. Doctors require change management. But the Agent platform offers a truly transformational approach, one that can harness voice to assist providers in their everyday duties and the work they perform within the consult room. So I'd say that does mean we anticipate seeing gains as time goes on. And naturally, there are likely M&A effects reflected in that as well, since as more clinics join the network, it becomes an overall blended figure that we're giving you. Still, we are confident that providers' core productivity will rise, particularly as Agentic capabilities in this sector continue to emerge.
All right. Turning to CyberWell, you said the company may be seeking an outside capital partner to help finance growth. Could you describe the kinds of opportunities you'd want this unit to go after? And what amount of capital are we discussing?
We haven’t spent much time locking down that figure yet. Still, I’d say this: at the outset, our plan isn’t to seek more than $10 million. Conversations are already underway with some parties. The person running CyberWell previously had a major exit in the cybersecurity company he led in the United States, where the backers were highly recognizable venture and private equity investors. As a result, we have strong confidence that under Jeffrey Engel’s leadership, we can attract capital. We’re also seeing demand for what CyberWell provides grow steadily. So data protection, I believe, will remain a very meaningful element of our story. And yes, we’re eager to work alongside investors to fulfill the mission there.
That brings us to the end of the question-and-answer session. I'll now hand things back to Hamed Shahbazi, who will offer some closing remarks.
I wanted to express my appreciation to all of you for joining us today. We're eager to talk with you once more in August. In the interim, we'll update you on each of the major strategic initiatives we discussed during this call, and we look forward to sharing news whenever it becomes available. Many thanks, and enjoy the rest of your day.
That wraps up today's conference call, everyone. We appreciate your participation, and please go ahead and disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete WELL Health Technologies Corp. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to WELL Health Technologies Corp. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.